Marker Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. (Nasdaq: MRKR) is a U.S.-based clinical-stage biotechnology company focused on immuno-oncology and next-generation T-cell therapies. Headquartered in Houston, Texas, and listed on the NASDAQ market in the United States, Marker is best understood as a development-stage small cap whose investment case is driven by scientific differentiation and clinical execution rather than near-term commercialization. The company’s roots are closely tied to Baylor College of Medicine in Houston, where its MAR-T platform was developed. Marker formally relocated its corporate headquarters from Jacksonville, Florida to Houston in 2019, strengthening its access to the Texas Medical Center ecosystem and to one of the most active cell-therapy communities in the United States. Its corporate history also reflects a series of merger and restructuring steps that transformed an originally private Marker entity into the current public company. Marker’s core business is the development of MAR-T cell therapies: non-genetically engineered T cells designed to recognize multiple tumor-associated antigens. This multi-antigen approach is intended to address one of the main limitations of cancer immunotherapy, namely tumor escape through antigen loss or heterogeneity. The company’s lead clinical programs currently highlighted in public disclosures include MT-601, aimed at hematologic malignancies and also being developed in solid tumors such as pancreatic cancer, and MT-401, which is being evaluated in a Phase 1 RAPID study as an off-the-shelf product for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). From a competitive standpoint, Marker operates in a crowded and capital-intensive landscape dominated by CAR-T franchises, cell-therapy specialists, and larger well-funded biopharma players. Its relative appeal lies in its differentiated platform design, the potential manufacturing simplicity of a non-genetically engineered approach, and the breadth of tumor targets covered by the platform. However, the company still needs to prove durable clinical efficacy, scalable manufacturing, and regulatory viability. As a result, the stock remains highly sensitive to clinical readouts, financing conditions, and partnership opportunities. Geographically, Marker remains primarily U.S.-centric, with its operations and R&D infrastructure centered in Houston. Recent notable developments include the release of year-end 2025 corporate and financial results in March 2026, continued advancement of MT-601 in pancreatic cancer supported by non-dilutive NIH/SBIR and CPRIT funding, and the first patient dosed in the RAPID study for MT-401. For investors, MRKR should therefore be viewed as a high-risk, event-driven biotech name whose valuation depends on pipeline progress and non-dilutive funding rather than current revenue generation.